These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome. Greber-Platzer S; Schatzmann-Turhani D; Wollenek G; Lubec G Biochem Biophys Res Commun; 1999 Jan; 254(2):395-9. PubMed ID: 9918849 [TBL] [Abstract][Full Text] [Related]
10. The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Wolvetang EW; Bradfield OM; Tymms M; Zavarsek S; Hatzistavrou T; Kola I; Hertzog PJ Biochim Biophys Acta; 2003 Jul; 1628(2):105-10. PubMed ID: 12890557 [TBL] [Abstract][Full Text] [Related]
11. Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene. Groner Y; Elroy-Stein O; Avraham KB; Yarom R; Schickler M; Knobler H; Rotman G J Physiol (Paris); 1990; 84(1):53-77. PubMed ID: 1972759 [TBL] [Abstract][Full Text] [Related]
12. ERF: genomic organization, chromosomal localization and promoter analysis of the human and mouse genes. Liu D; Pavlopoulos E; Modi W; Moschonas N; Mavrothalassitis G Oncogene; 1997 Mar; 14(12):1445-51. PubMed ID: 9136988 [TBL] [Abstract][Full Text] [Related]
13. In vivo modulation of ETS genes induced by electromagnetic fields. Mucci N; Ianni A; Ursini CL; Arzani D; Bhat NK; Navarra P; Romano-Spica V In Vivo; 2001; 15(6):489-94. PubMed ID: 11887334 [TBL] [Abstract][Full Text] [Related]
14. Expression of the transcription factor ETS2 in brain of patients with Down syndrome--evidence against the overexpression-gene dosage hypothesis. Greber-Platzer S; Schatzmann-Turhani D; Cairns N; Balcz B; Lubec G J Neural Transm Suppl; 1999; 57():269-81. PubMed ID: 10666682 [TBL] [Abstract][Full Text] [Related]
15. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Wolvetang EJ; Wilson TJ; Sanij E; Busciglio J; Hatzistavrou T; Seth A; Hertzog PJ; Kola I Hum Mol Genet; 2003 Feb; 12(3):247-55. PubMed ID: 12554679 [TBL] [Abstract][Full Text] [Related]
16. Hematopoietic deficiencies and core binding factor expression in murine Ts16, an animal model for Down syndrome. Gjertson C; Sturm KS; Berger CN Clin Immunol; 1999 Apr; 91(1):50-60. PubMed ID: 10219254 [TBL] [Abstract][Full Text] [Related]
17. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Sapi E; Flick MB; Rodov S; Kacinski BM Cancer Res; 1998 Mar; 58(5):1027-33. PubMed ID: 9500466 [TBL] [Abstract][Full Text] [Related]
18. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223 [TBL] [Abstract][Full Text] [Related]
19. Gene for porcine pregnancy-associated glycoprotein 2 (poPAG2): its structural organization and analysis of its promoter. Szafranska B; Miura R; Ghosh D; Ezashi T; Xie S; Roberts RM; Green JA Mol Reprod Dev; 2001 Oct; 60(2):137-46. PubMed ID: 11553911 [TBL] [Abstract][Full Text] [Related]
20. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Tymms MJ; Ng AY; Thomas RS; Schutte BC; Zhou J; Eyre HJ; Sutherland GR; Seth A; Rosenberg M; Papas T; Debouck C; Kola I Oncogene; 1997 Nov; 15(20):2449-62. PubMed ID: 9395241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]